Patheon

Integrating development, manufacturing, and research processes enhances e¬ciency and accelerates time to market

The concept of patient centricity is gaining significant traction in the pharmaceutical industry, reshaping the way drugs are developed and produced. This report, developed in partnership with CPHI, specifically explores how optimizing the pharmaceutical supply chain can help improve patient-centricity, and showcases examples of it already being implemented at large. Additionally, the report addresses the increasing role CDMOs and CROs are playing in servicing patients at the end of the pharmaceutical development and manufacturing pipeline.

***Session 1: Thursday, April 22, 2021, 10am EDT, Session 2: Thursday, April 22, 2021, 11am EDT, Session 3: Thursday, April 22, 2021, 1pm EDT*** A drug’s journey from development to manufacturing to patients is paved with roadblocks and potholes; many threats can derail bio/pharmaceutical processes. Potential solutions to such pitfalls have been discussed for years; however, few manufacturers have embraced technology and process advances to proactively ensure drug supply chain continuity.

The market momentum of novel therapies targeting unmet needs is creating a new landscape for pharmaceutical drug manufacturers. As the focus on these smaller patient pools grows, so does the complexity of drug development. Companies must understand how the molecules filling today’s pipeline are changing our business, as they are causing a dramatic shift in how we plan for and execute drug development and manufacturing.

Technology transfers helps sponsors safeguard supply, improve distribution and reduce program costs and risks.

#wpbut {border: 3px solid #245998; border-radius:40px; border-color: #245998; padding: 15px 30px; font-size:15px !important;} #wpbut:hover {background: #15355a; color: #fff !important; transition: .5s;}